fda warning compounding semaglutide october 2025 Warns on Certain Forms of Compounded fda compounding semaglutide warning letters

If the scheduled date was more than 5 days ago, skip the dose and take the next scheduled dose according to your treatment plan

Before determining that a shortage is resolved, FDA considers a variety of factors, including the company's ability to meet current and historical demand, the amount in a manufacturers stock, affected market share, ability of alternate manufacturers to cover the demand, and confirmed market stabilization

this warrants ongoing monitoring No unexpected serious cardiovascular signals were identified during the limited Phase 2 follow-up period, though the trials were neither designed nor powered to assess cardiovascular outcomes, and longer-term data are not yet available At present, the overall safety profile appears broadly consistent with other GLP-1-based therapies, but definitive conclusions cannot be drawn until Phase 3 data and post-marketing surveillance are available

Many factors can influence your individual experience